Dr. Shih is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
50 Northern Ave
Boston, MA 02210
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2006 - 2009- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2006
University of WashingtonInternship, Internal Medicine, 2003 - 2004
University of California San Francisco School of MedicineClass of 2003
Certifications & Licensure
MA State Medical License 2006 - 2026
OR State Medical License 2017 - 2025
WA State Medical License 2017 - 2018
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Publications & Presentations
PubMed
- 1 citationsSafety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis.Paul McNally, Alvin Singh, Susanna A McColley, Jane C Davies, Mark Higgins
Journal of Cystic Fibrosis. 2024-05-01 - 5 citationsLong-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.Patrick A Flume, R Scott Harris, Hildegarde Paz-Diaz, Neil Ahluwalia, Mark Higgins
Journal of Cystic Fibrosis. 2023-05-01 - Registry-based study in people with cystic fibrosis and anvariant treated with ivacaftor.Mark Higgins, Thalia Farietta, Daniel Campbell, Meng Liu, Josh Ostrenga
BMJ Open Respiratory Research. 2023-05-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
